$3.27
0.46% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Dare Bioscience, Inc. Stock price

$3.27
-0.17 4.94% 1M
-3.32 50.36% 6M
-0.44 11.81% YTD
-2.25 40.76% 1Y
-17.73 84.43% 3Y
-6.09 65.06% 5Y
-475.53 99.32% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.02 0.46%
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Key metrics

Market capitalization $27.82m
Enterprise Value $17.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.07
P/S ratio (TTM) P/S ratio 9.80
P/B ratio (TTM) P/B ratio 10.41
Revenue (TTM) Revenue $2.84m
EBIT (operating result TTM) EBIT $-26.84m
Free Cash Flow (TTM) Free Cash Flow $-10.98m
Cash position $16.41m
EPS (TTM) EPS $-0.98
P/E forward negative
P/S forward 15.04
EV/Sales forward 9.32
Short interest 0.46%
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Dare Bioscience, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2.84 2.84
-
100%
- Direct Costs 0.05 0.05
150% 150%
2%
2.79 2.79
14,050% 14,050%
98%
- Selling and Administrative Expenses 11 11
10% 10%
383%
- Research and Development Expense 19 19
34% 34%
659%
-27 -27
34% 34%
-944%
- Depreciation and Amortization 0.05 0.05
150% 150%
2%
EBIT (Operating Income) EBIT -27 -27
34% 34%
-945%
Net Profit -7.20 -7.20
82% 82%
-254%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2024 Earnings Call Transcript August 12, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright & Co. Operator Welcome to the conference call hosted by Daré Bioscience to review the company's second quarter fi...
Neutral
GlobeNewsWire
about 2 months ago
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational ...
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock bei...
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 26
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today